Skip to Main Content

This has been a blockbuster year for federal regulators investigating bribery in the pharmaceutical industry.

Three of the world’s biggest drug companies, along with two smaller companies, agreed to pay a collective $63 million this year to settle allegations that they violated the US Foreign Corrupt Practices Act by bribing doctors and government officials to promote their medicines overseas.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!